Loss of autophagy affects melanoma development in a manner dependent on PTEN status

Mathias T. Rosenfeldt1,2,3 · Jim O’Prey1 · Colin R. Lindsay1 · Colin Nixon1 · Sabine Roth3 · Owen J. Sansom1,4 · Kevin M. Ryan1,4

Received: 9 July 2020 / Revised: 15 January 2021 / Accepted: 28 January 2021 / Published online: 4 March 2021

© The Author(s) 2021. This article is published with open access

(Macro)Autophagy is a process that delivers cellular constituents for lysosomal degradation. Autophagy is important in cancer with both pro- and anti-tumourigenic roles being reported [1]. Melanoma is a cancer originating from melanocytes and frequently develops in UV-exposed skin [2]. To examine autophagy’s role in melanoma we utilized a mouse model containing an allele of the 

Braf

V600E mutation (the signature molecular driver of human melanoma [3]) preceded by a Lox-STOP-Lox cassette [4]. These mice were crossed to animals bearing a floxed allele of 
Pten, which can accelerate the disease, and/or animals carrying floxed alleles of the essential autophagy gene 

Atg7 [5, 6]. Recombination of alleles was achieved by topical application of tamoxifen to activate an inducible Cre-recombinase (Cre-ER) under control of the Tyrosinase (Tyr) promoter [7]. In 

Braf

V600E mice wild-type for 
Pten (Tyr-Cre:ER 
Pten+/+ 

Braf

V600E/+) deletion of 

Atg7 (Tyr-Cre:ER 
Pten+/+ 

Braf

V600E/+ 

Atg7−/−) significantly accelerated melanoma onset (Fig. 1, Table S1). In contrast, in mice hemizygous for 
Pten (Tyr-Cre:ER 
Pten+/− 

Braf

V600E+) melanoma onset was accelerated, but no difference was observed upon 

Atg7 deletion (Fig. 1, Table S2). Immunohistochemistry for ATG7, LC3 and p62/SQSTM1 established the presence/absence of autophagy and positivity for S100 confirmed melanocytic origin of tumour cells (Fig. S1). Our findings show autophagy is dispensable for melanoma growth and might support a barrier function for melanoma development that is compromised in animals hemizygous for 
Pten that eventually lose the remaining wild-type allele during disease progression [5].

A potential explanation for our findings might be the connection between autophagy and senescence. Senescence is a terminal cell cycle arrest that serves as a barrier to block malignant progression [8]. Nevi can progress to melanoma if the senescent barrier is breached and downregulation of ATG5 prevents oncogene-induced senescence in primary human melanocytes [9]. As our model develops senescent nevi before invasive melanoma occurs [4], it is conceivable that acceleration of melanoma onset upon 

Atg7 deletion is due to a senescence defect. This suggests that 

Atg7-deletion should not have the same impact in the context of 
Pten-deficiency, as PI3K pathway activation via 
Pten deletion is known to abrogate oncogene-induced senescence and contributes to melanoma development [10]. The pro-senescence features of autophagy would then be superfluous and autophagy-deletion would not impact on melanoma onset.

Our results are in contrast to work from Xie and colleagues who found that 

Atg7-deletion prevents tumour formation in the context of 
Pten deletion [11]. A possible explanation for this discrepancy is the different models used. Xie et al. used mice that upon 

BrafV600E activation developed pigmented skin lesions, but failed to progress to invasive melanoma unless combined with loss of PTEN, which would impair senescence from the outset of tumour development [5, 10, 11]. In this case, autophagy loss impairs disease progression by modulating oxidative stress. In contrast, we relied on a different model [4] in which 

BRAFV600E expression alone is sufficient for melanoma development once the senescence barrier is breached at a point during disease progression or, in our case, when combined with loss of an essential autophagy gene.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41418-021-00746-7.

Mathias T. Rosenfeldt mathias.rosenfeldt@uni-wuerzburg.de
Kevin M. Ryan k.ryan@beatson.gla.ac.uk

1 Cancer Research UK Beatson Institute, Glasgow, UK
2 Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany
3 Department of Pathology, University of Wuerzburg, Wuerzburg, Germany
4 Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
The reason for the different phenotypic effects seen in these two models of melanoma is unknown. It may be that subtle differences in the strategies for gene targeting [12, 13], the use of different Cre lines [7, 14] or differences in the strain background of the animals used in the different studies could all contribute to the differences observed. While this is however speculation, what is clear is that the profound phenotypic differences observed imply significant genetic intricacies that lead to different autophagy dependencies that are affected by Pten status in these two mouse models.

It is natural to question how these findings relate to the role of autophagy in human melanoma. Like in many cancers, autophagy is considered tumour suppressive in the transition from benign to malignant disease, but conversely tumour promoting in established melanoma [15, 16]. Our data support a tumour preventive role in the early stages of melanoma development, and as mentioned above, a previous study has shown that ATG5 is down-regulated at this stage of human melanoma resulting in enhanced proliferation and bypass of senescence [9]. Another study also showed that hemizygous loss of ATG5 occurs during melanoma development [17], but as loss of one allele of ATG5 would not be predicted to inhibit autophagy, this raises the question whether the driver for this loss is an autophagy-independent effect of ATG5. However, while these caveats are possible, there is clear evidence that accumulation of the autophagic substrate p62/SQSTM1 is pro-tumorigenic [18, 19], suggesting that there is pressure to lose or at least temporarily inactivate autophagy during the progression of this disease.

**Methods**

**Animal experiments**

Mouse strains were described previously [4–6] and of C57BL/6 background. All experiments were carried out in compliance with UK Home Office regulations (Project license number: P54E3DD25). Melanocyte specific recombination was achieved by topical application of 1 mg/d tamoxifen for five consecutive days on the shaven back to activate an inducible Cre-recombinase under control of the Tyrosinase (Tyr) promoter [7]. Experimental mice were 73 +/- 7d old and of equal gender distribution. Animals were monitored thrice weekly for tumour formation and sacrificed once end point criteria were met (melanoma >= 15 mm, ulceration, significant weight loss, weakness and inactivity). Kaplan–Meier curves represent time to tumour onset. Censored animals had to be sacrificed because they reached endpoint criteria or old age without evidence of melanoma.

**Statistical analyses**

Statistical analyses were carried out using IBM SPSS Statistics version 21 for Windows. A log-rank test was used to determine significance in Kaplan-Meier curves.

**Funding**

This work was supported by grants from Cancer Research UK to KMR (A22903 and A17196) and OJS (A21139 and A17196) and a grant from the German Research Foundation to MTR (DFG/FOR2314).

**Author contributions** MTR, OJS, and KMR conceived the study. MTR, JOP, CL, and SR conducted experiments. MR, JOP, CN, and KMR analyzed experiments. MTR and KMR wrote the paper.

**Compliance with ethical standards**

**Conflict of interest** The authors declare no competing interests.

**Ethics** All experiments were carried out in compliance with UK Home Office regulations (Project license number: P54E3DD25).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mainz L, Rosenfeldt MT. Autophagy and cancer - insights from mouse models. FEBS J. 2018;285:792–808.
2. Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 2021;141:23–31.
3. Hill VK, Gartner JJ, Samuels Y, Goldstein AM. The genetics of melanoma: recent advances. Annu Rev Genomics Hum Genet. 2013;14:257–79.
4. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009;15:294–303.
5. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544–52.
6. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, et al. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005;169:425–34.
7. Yajima I, Belloir E, Bourgeois Y, Kumasaka M, Delmas V, Larue L. Spatiotemporal gene control by the Cre-ERT2 system in melanocytes. Genesis. 2006;44:34–43.
8. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuijlman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005; 436:720–4.
9. Liu H, He Z, von Rutte T, Yousefi S, Hunger RE, Simon HU. Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Sci Transl Med. 2013;5:202ra123.
10. Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 2012;26:1055–69.
11. Xie X, Koh JY, Price S, White E, Mehrrt JM. Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 2015;5:410–23.
12. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 2007;21:379–84.
13. Mercier K, Giblett S, Green S, Lloyd D, DaRocha Dias S, Plumb M, et al. Expression of endogenous oncogenic V600E-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res. 2005;65:11493–11500.
14. Bosenberg M, Mathusamy V, Curley DP, Wang Z, Hobbs C, Nelson B, et al. Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis. 2006;44:262–7.
15. Corazzari M, Fimia GM, Lovat P, Piacentini M. Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. Semin Cancer Biol. 2013;23:337–43.
16. Rahmati M, Ebrahim S, Hashemi S, Motamedi M, Moosavi MA. New insights on the role of autophagy in the pathogenesis and treatment of melanoma. Mol Biol Rep. 2020;47:9021–32.
17. Garcia-Fernandez M, Karras P, Checinska A, Canon E, Calvo GT, Gomez-Lopez G, et al. Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5. Autophagy. 2016;12:1776–90.
18. Ellis RA, Horswell S, Ness T, Lumsdon J, Tooze SA, Kirkham N, et al. Prognostic impact of p62 expression in cutaneous malignant melanoma. J Invest Dermatol. 2014;134:1476–8.
19. Karras P, Riveiro-Falkenbach E, Canon E, Tejedo C, Calvo TG, Martinez-Herranz R, et al. p62/SQSTM1 fuels melanoma progression by opposing mRNA decay of a selective set of pro-metastatic factors. Cancer Cell. 2019;35:46–63.e10.